Medical Device

ALR Technologies ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, today announces that the Company has released a new investor presentation that can be viewed at www.ALRT.cominvestors . The Company invites investors and interested parties to explore the recently redesigned corporate website.

"ALRT is at an inflection point, moving forward with high-level negotiations and due diligence processes that will be transformational to the fundamentals of our company. We want to ensure that our presentation and website concisely convey our strategic positioning in the human and animal diabetes markets as innovators of product, services, technology and big data," commented Sidney Chan, Chairman and CEO at ALR Technologies. "Our team, which includes the key additions of Joe Stern as Head of Animal Health, Pete Riojas as Head of Global Commercial and Business Development, and Jacqueline Wu as Head of Corporate Marketing, looks forward to a consistent flow of announcements providing ALRT investors a transparent view of our developments over the coming weeks and months."

About ALR Technologies

ALR Technologies is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an algorithm to provide prescribers support for timely non-insulin medication advancements. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. The program tracks performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes Solution gives healthcare providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.

In addition, the animal health division has identified an unmet need in diabetes care and has developed a solution to assist veterinarians in determining the effectiveness of insulin and helping to identify the appropriate dose and frequency of administration for companion animals. Thus, delivering the same optimization of diabetic drug therapies to pets as to humans.

ALR Technologies SG Pte. Ltd. is a wholly owned subsidiary of ALR Technologies Inc. On June 1, 2021, ALR Technologies Inc. announced its intention to migrate to Singapore. More information about ALR Technologies Inc. can be found at www.alrt.com. Regarding ALR Technologies SG Pte. Ltd. Information can be found at https://sg.alrt.com.

Contact

Ken Robulak (US)
Phone: +1 (727) 736-3838

Anthony Ngai (Singapore)
Phone: +65 3129 2924

Email: ir@alrt.com

This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties, and assumptions. When used, the words "estimate", "expect", "anticipate", "believe", "will" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance, or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the Company's quarterly filings with the Securities Exchange Commission.


News Provided by GlobeNewswire via QuoteMedia

Medtronic executives to speak at the Evercore ISI 5th annual HealthCONx conference

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the Evercore ISI 5 th annual HealthCONx conference on Tuesday, November 29 2022.

Geoff Martha , Medtronic chairman and chief executive officer, and Karen Parkhill , executive vice president & chief financial officer, will answer questions on the company beginning at 5:10 p.m. EST ( 4:10 p.m. CST ).

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
2 Biggest Medical Device ETFs in 2022

2 Biggest Medical Device ETFs in 2022

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less

Medtronic reports second quarter fiscal 2023 financial results

Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes

Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2023, which ended October 28, 2022 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 10:30 a.m. (EST).

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology

  • The Consumer Technology Association (CTA) awards Abbott multiple CES 2023 Innovation Awards for industry-leading health technologies
  • Abbott's Aveir™ single-chamber (VR) leadless pacemaker, Proclaim™ Plus SCS system, Alinity ® m Monkeypox PCR test honored
  • Other recent Abbott innovation honors include Abbott's FreeStyle Libre ® technology named the best medical technology in the last 50 years by the Galien Foundation

- Abbott (NYSE: ABT) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show (CES), the most influential technology event in the world.

Ahead of the CES 2023 event, three of Abbott's industry-leading tech advancements won CES 2023 Innovation Awards , all within the Digital Health award category:

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") announced today that on November 14, 2022 it priced an offering of €1.25 billion aggregate principal amount (the "Offering") of the following euro-denominated notes:

  • €500,000,000 aggregate principal amount of its 3.200% senior notes due 2026 (the "2026 notes"), at the issue price of 99.965% of their principal amount, and
  • €750,000,000 aggregate principal amount of its 3.650% senior notes due 2034 (the "2034 notes" and together with the 2026 notes, the "notes"), at the issue price of 99.637% of their principal amount.

The Offering is expected to close on or about November 21, 2022, subject to customary closing conditions. The notes will pay interest on an annual basis.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×